Boston Scientific said it entered into a $2 billion accelerated share repurchase agreement with JPMorgan Chase as part of its previously authorized $5 billion buyback program. The company expects to receive about 30.4 million shares initially and said final settlement is due by June 30, 2026.

Boston Scientific said it has entered into a $2 billion accelerated share repurchase agreement with JPMorgan Chase Bank, National Association, as part of its previously announced $5 billion share repurchase authorization.

The company said it expects to receive common stock with an aggregate value equal to 80% of the repurchase price initially, or about 30.4 million shares based on the May 15, 2026 closing price of $52.68. Final settlement of the transaction is expected by June 30, 2026.

What it means

After the ASR is completed, Boston Scientific said $3 billion will remain available under the authorization. The company also said the transaction is expected to have a net $0.02 adjusted EPS impact in full-year 2026.

The announcement adds another layer to Boston Scientific's ongoing capital return program, but the company did not indicate any change to its broader repurchase authorization beyond the new agreement.

Revision note

Initial automated publication.